@entity157 : XXXX followed by a @entity632 -ethiodized oil emulsion and gelatin sponge powder.

@entity632 @entity1 @entity82 @entity63 @entity5 @entity1425 @entity157 @entity3990
PURPOSE: This study evaluates chemoembolization (CE) of the liver with minimal vasoconstriction followed by selective intraarterial delivery of an emulsion of @entity3990 , @entity632 , and ethiodized oil and temporary occlusion of hepatic artery with gelatin sponge powder in @entity1 with @entity157 . @entity1 AND METHODS: Since 1988, 30 @entity1 with nonresectable @entity157 underwent CE with the above protocol. Intraarterial @entity1425 (0.5-1 microgram diluted in 10 mL of saline) was rapidly injected directly into the proper hepatic artery or selectively into the right or left hepatic arteries and was followed by 40-60 mg of @entity632 dissolved in 10 mL of @entity3990 and emulsified in 20 mL of ethiodized oil. The chemoembolic mixture was injected at the rate of arterial flow. Liver function and clotting parameters were monitored three times a day until there was a downward trend toward preembolic levels. Computed tomography (CT) was performed immediately after embolization and at 1-3-month intervals. Embolization was repeated when CT demonstrated recurrent or progressive disease. RESULTS: Disease recurred or progressed in 11 @entity1 at 2-17 months after embolization. CE was repeated in four @entity1 ; one individual underwent three embolizations. Re-embolization was performed up to 14 months after initial embolization (median, 10 months). Five @entity1 (16.7%) died within 1 month of embolization. Ten @entity1 died at 3-33 months after CE. Two of these @entity1 died of @entity82 at 6 and 14 months, without evidence of recurrent @entity5 . Fifteen @entity1 remain alive 5-28 months after CE. Kaplan-Meier estimation of probability of survival curves demonstrates a median survival of 14 months. Sixty-one percent of @entity1 were alive at 1 year and 36% at 2 years after the procedure. CONCLUSION: CE with use of the above technique is effective for palliating inoperable @entity157 . It causes a significant prolongation of survival over the expected 18-24 weeks in untreated @entity1 ; this may occur because high doses of chemotherapeutic agents are delivered and come in contact with the @entity5 for a longer period, followed by @entity63 brought about by temporary arterial occlusion.
